相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
Milton Packer
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis
Jonathan P. Troost et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
John J. V. McMurray et al.
CIRCULATION (2021)
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
David Z. I. Cherney et al.
DIABETOLOGIA (2021)
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler et al.
KIDNEY INTERNATIONAL (2021)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney et al.
Lancet Diabetes & Endocrinology (2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
Radko Komers et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Carol Pollock et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Predicting individual treatment response in diabetes
Hiddo J. L. Heerspink
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
T. Cooper Woods et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Advanced therapeutics in focal and segmental glomerulosclerosis
Yunzi Liu et al.
NEPHROLOGY (2018)
An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis
Jonathan P. Troost et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
Hiddo J. Lambers Heerspink et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis
Lesley A. Inker et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Clinical trial of focal segmental glomerulosclerosis in children and young adults
Debbie S. Gipson et al.
KIDNEY INTERNATIONAL (2011)
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
Anita McGrogan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Focal Segmental Glomerulosclerosis
Vivette D. D'Agati et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases
Laura Barisoni et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
分享论文
